Adamas Pharmaceuticals, Inc.: Series D $40M

Posted in I - Series D, Q - 3Q09, R - WEST, X - Antiinfective, X - CNS, X - Dementia, X - Influenza, X - Parkinson's, XX - CA

Adamas Pharmaceuticals (Emeryville, CA) a development-stage small molecule company focused on neurological (Parkinson’s and dementia) and infectious (influenza) diseases, closed a $40M Series D financing. Participants include Aeris Capital, DAG Ventures, Mohr Davidow Ventures and Northgate Capital.

Jun

2009

Avid Radiopharmaceuticals, Inc.: Series D $34.5M

Posted in I - Series D, Q - 2Q09, R - NORTH EAST, X - Alzheimer's, X - Dementia, X - Diabetes, X - Imaging, X - Parkinson's, XX - PA

Avid Radiopharmaceuticals (Philadelphia, PA) a development-stage company focused on molecular imaging compounds for diagnostic and detection use in Alzheimer’s, dementia, Parkinson’s and diabetes, closed a $24.5M Series D financing. Participants include Alta Partners, AllianceBernstein, Safeguard Scientifics, Pfizer Venture Investments, Lilly Ventures, RK Ventures Group and BioAdvance.

Mar

2009

Heptares Therapeutics, Ltd.: Series A $29.9M

Posted in I - Series A, Q - 1Q09, R - INTERNATIONAL, X - G-Protein, X - Parkinson's

Heptares Therapeutics (United Kingdom) a discovery-stage company focused on small-molecule drugs targeting G-protein-coupled receptors whose lead indication is Parkinson’s, closed a $29.9M Series A financing. Participants include Clarus Ventures, MVM Life Science Partners and Novartis Ventures Option Fund.

Jan

2009

Satori Pharmaceuticals, Inc.: Series B $22M

Posted in I - Series B, Q - 1Q09, R - NORTH EAST, X - Alzheimer's, X - Neurology, X - Parkinson's, XX - CA

Satori Pharmaceuticals (Cambridge, MA) an early-stage neuroscience company focused on the discovery and development of therapies for Alzheimer’s, Parkinson’s disease and other neurodegenerative disorders closed a $22M Series B financing. Participants include InterWest Partners, Prospect Venture Partners, New Enterprise Associates and PureTech Ventures.

to top of page...